N-Carbonyl-L-alanin-ethylester | 33280-95-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Carbonyl-L-alanin-ethylester
• 英文别名: Propanoic acid, 2-isocyanato-, ethyl ester, (2S)-；ethyl (2S)-2-isocyanatopropanoate
• CAS: 33280-95-4
• 化学式: C₆H₉NO₃
• 分子量: 143.142
• InChiKey: PFIQRPNWLUAMOF-YFKPBYRVSA-N

物化性质

• 沸点：
  166.1±23.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈（少量）、氯仿（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  55.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-Carbonyl-L-alanin-ethylester 在 三(2-氯乙基)胺 作用下， 以 苯 为溶剂， 反应 17.0h， 生成 N-<1-(5'-O-tert-Butyldimethylsilyl-2',3'-O-isopropyliden-β-D-ribofuranosyl)-5-tetrazolyl>-L-alanin-ethylester
  参考文献：
  名称：

  Zbiral, Erich; Schoerkhuber, Wolfgang, Liebigs Annalen der Chemie, 1982, # 10, p. 1870 - 1890

  摘要：

  DOI：
• 作为产物：
  描述：

  光气 、 L-丙氨酸乙酯盐酸盐 在 吡啶 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 以72%的产率得到N-Carbonyl-L-alanin-ethylester
  参考文献：
  名称：

  An improved method for the synthesis of enantiomerically pure amino acid ester isocyanates

  摘要：

  DOI：

  10.1021/jo00052a069

文献信息

• [EN] TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS<br/>[FR] ANTAGONISTES DE TRPM8 ET LEUR UTILISATION DANS LE CADRE THÉRAPEUTIQUE
  申请人：AMGEN INC

  公开号：WO2012177896A1

  公开（公告）日：2012-12-27

  Compounds of Formula (I) are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula (I) have the above structure, where the definitions of the variables are provided herein.

  式（I）的化合物可用作TRPM8的拮抗剂。这些化合物在治疗许多TRPM8介导的疾病和症状方面具有用处，并可用于制备用于治疗这些疾病和症状的药物和药物组合物。这些疾病的例子包括但不限于偏头痛和神经病性疼痛。式（I）的化合物具有上述结构，其中变量的定义在此提供。
• TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS
  申请人：BROWN James

  公开号：US20130158034A1

  公开（公告）日：2013-06-20

  Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  式I的化合物是TRPM8拮抗剂，对于治疗许多TRPM8介导的疾病和症状有用，并可用于制备治疗此类疾病和症状的药物和制剂。此类疾病的例子包括但不限于偏头痛和神经病性疼痛。式I的化合物具有以下结构：其中变量的定义在此提供。
• Nucleoside Transport Inhibitors: Structure−Activity Relationships for Pyrimido[5,4-<i>d</i>]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α₁-Acid Glycoprotein
  作者：Kappusamy Saravanan、Hannah C. Barlow、Marion Barton、A. Hilary Calvert、Bernard T. Golding、David R. Newell、Julian S. Northen、Nicola J. Curtin、Huw D. Thomas、Roger J. Griffin

  DOI：10.1021/jm101493z

  日期：2011.3.24

  Membrane transport of nucleosides or nucleobases is mediated by transporters including the equilibrative nucleoside transporters (ENTs), and resistance to antitumor antimetabolite drugs may arise via salvage of exogenous purine or pyrimidine nucleosides or nucleobases by ENT transporters. The therapeutic utility of dipyridamole (3), a potent ENT inhibitor, is compromised by binding to the serum protein alpha(1)-acid glycoprotein (AGP). Derivatives and prodrugs of the ENT inhibitor 4,8-bis[(3,4-dimethoxybenzyl)amino]-2,6-bis[(2-hydroxypropyl)amino]pyrimido[5,4-d]pyrimidine (6, NU3108) are described, with improved in vivo pharmacokinetic properties and reduced AGP binding relative to dipyridamole. The mono- and diglycine carbamate derivatives were at least as potent as 6 and showed no reduction in potency by AGP. In a [H-3]thymidine incorporation assay, employing COR-L23 cells, the diastereoisomers of 6 (IC50 = 26 nM) exhibited activity comparable with 3 (IC50 = 15 nM). The monophenyl carbamate and mono-4-methoxyphenyl carbamate exhibited the best ENT-inhibitory activity in the COR-L23 assay (IC50 =8 and 4 nM, respectively). All of the new prodrugs were also highly effective at reversing thymidine/hypoxanthine rescue from pemetrexed cytotoxicity in the COR-L23 cell line.
• Glykosylazide als Ausgangsbasis zur Gewinnung von Nucleosidanalogen, 3. Mitt. Synthese von Alkylaminotetrazol- und Uretidinonnucleosiden
  作者：Herbert Knotz、Erich Zbiral

  DOI：10.1007/bf00810753

  日期：1986.12
• Tesser,G.I.; Nivard,R.J.F., Recueil des Travaux Chimiques des Pays-Bas, 1964, vol. 83, p. 53 - 66
  作者：Tesser,G.I.、Nivard,R.J.F.

  DOI：——

  日期：——